CorMedix (CRMD) Accounts Payables (2010 - 2026)
CorMedix (CRMD) posted Accounts Payables of $7.9 million for Q4 2025, down 61.46% sequentially from $20.5 million in Q3 2025, and up 358.37% YoY from $1.7 million in Q4 2024.
CorMedix (CRMD) Accounts Payables (2010 - 2026) Analysis & Trends
CorMedix has reported Accounts Payables for 15 years, with the latest figure at $7.9 million in Q4 2025.
- Quarterly Accounts Payables rose 358.37% year-over-year to $7.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.9 million (up 358.37% YoY) and the FY2025 annual result came in at $7.9 million, up 358.37% from the prior year.
- Accounts Payables retreated to $7.9 million in Q4 2025 per CRMD's latest filing, from $20.5 million in the prior quarter.
- Over five years, Accounts Payables peaked at $20.5 million in Q3 2025 and troughed at $943344.0 in Q2 2021.
- A 5-year average of $3.5 million and a median of $2.2 million in 2021 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables plunged 59.81% in 2024, then soared 1422.09% in 2025.
- Over 5 years, Accounts Payables stood at $2.2 million in 2021, then retreated by 0.34% to $2.2 million in 2022, then jumped by 94.34% to $4.3 million in 2023, then tumbled by 59.81% to $1.7 million in 2024, then jumped by 358.37% to $7.9 million in 2025.
- According to Business Quant data, Accounts Payables over the past three periods registered $7.9 million, $20.5 million, and $5.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | CorMedix | 645.20 Mn | 388.51 Mn | 77.13 Mn | 10.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.24 Mn |
| Dec 31, 2025 | 7.88 Mn |
| Sep 30, 2025 | 20.45 Mn |
| Jun 30, 2025 | 5.82 Mn |
| Mar 31, 2025 | 1.93 Mn |
| Dec 31, 2024 | 1.72 Mn |
| Sep 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 3.34 Mn |
| Mar 31, 2024 | 2.83 Mn |
| Dec 31, 2023 | 4.28 Mn |
| Sep 30, 2023 | 2.39 Mn |
| Jun 30, 2023 | 2.90 Mn |
| Mar 31, 2023 | 1.45 Mn |
| Dec 31, 2022 | 2.20 Mn |
| Sep 30, 2022 | 1.77 Mn |
| Jun 30, 2022 | 2.50 Mn |
| Mar 31, 2022 | 1.74 Mn |
| Dec 31, 2021 | 2.21 Mn |
| Sep 30, 2021 | 1.11 Mn |
| Jun 30, 2021 | 943,344.00 |